Smit Kour

Affiliations: 
2016-2020 University of Nebraska Medical Center, Omaha, NE, United States 
Google:
"Smit Kour"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Robb CM, Kour S, Contreras JI, et al. (2020) Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 11: 2462-2463
Rana S, Kour S, Sonawane YA, et al. (2020) Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK. Chemical Biology & Drug Design
Kour S, Rana S, Contreras JI, et al. (2019) CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429
Rana S, Bendjennat M, Kour S, et al. (2019) Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic & Medicinal Chemistry Letters
Contreras JI, Robb CM, King HM, et al. (2018) Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology
Robb CM, Kour S, Contreras JI, et al. (2018) Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 9: 5216-5232
Robb CM, Contreras JI, Kour S, et al. (2017) Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chemical Communications (Cambridge, England)
See more...